Drug intelligence / Profile preview

[11C]PiB + [18F]DPA-714

Development stage: Preclinical
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[11C]PiB (Pittsburgh Compound B) and [18F]DPA-714 are radiopharmaceuticals used together in positron emission tomography (PET) imaging studies, particularly for Alzheimer's disease research. [11C]PiB binds to amyloid-beta plaques, while [18F]DPA-714 is a radiotracer that targets the 18-kDa translocator protein (TSPO), which is overexpressed in activated microglia during neuroinflammation. This combination allows researchers to simultaneously assess amyloid plaque burden and neuroinflammatory processes in the brain[2][3][9].

Targets

TSPO (Translocator Protein (18 kDa))

Beyond the preview

Go deeper on [11C]PiB + [18F]DPA-714.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [11C]PiB + [18F]DPA-714.

Explore the full profile